Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7652W HIGH $2.03
Volume
29.03 K
Value Traded
259.76 K
Short % Float
2.52%
-6.55%Week
-13.71%1 Month
+5.94%3 Month
-14.4%6 Month
-91.52%5 Year
-95.74%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
20.61 M
EPS (TTM)
-0.52
P/E Ratio
-
Ent. Value
18.44 M
Total Shares
19.26 M
Float Shares
12.81 M
Insiders
33.53%
Institutions
5.77%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
COCP Catalyst Timeline
Dated clinical, regulatory and corporate events for Cocrystal Pharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cocrystal Pharma, Inc.
460Total events
2Upcoming
77Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Preclinical PoCPreclinical
Discovery of pan-viral inhibitors with in vitro potency against hantavirus
hantavirus, bunyavirus, influenzasource ↗
▲First Patient DosedCDI-988Trial
CDI-988 advanced to Phase 1b norovirus challenge study in the US
norovirussource ↗
▲Enrollment MilestoneCDI-988Trial
Began enrollment in prevention and treatment cohorts
norovirus infectionsource ↗
▲Fast Track DesignationCDI-988Designation
Granted FDA Fast Track designation for CDI-988
norovirus infectionsource ↗
◆Oral PresentationCDI-988Presentation
Oral presentation at ICAR 2026 highlighting mechanism of action and clinical advancement of CDI-988
Norovirus Infectionsource ↗
▲Enrollment CompleteCDI-988Trial
Completed enrollment of stage 1 infectivity cohort in Phase 1b challenge study
Norovirus Infectionsource ↗
◆Oral PresentationCDI-988Presentation
Presentation of Phase 1 data and updates from ongoing Phase 1b challenge study at ICAR2026
norovirus infectionsource ↗
▲Fast Track DesignationCDI-988Designation
FDA grants Fast Track designation for CDI-988 for norovirus infection treatment and prophylaxis
norovirus infectionsource ↗
▲Trial InitiationCDI-988Trial
Phase 1b norovirus challenge study underway at Emory University
norovirus infectionsource ↗
▲Enrollment CompleteCDI-988Trial
Completed enrollment in first cohort of Phase 1b challenge study
norovirus infectionsource ↗
●Oral PresentationCDI-988Presentation
Highlighted CDI-988’s mechanism of action and clinical advancement at ICAR 2026
norovirus infectionsource ↗
▲First Patient DosedCDI-988Trial
First subjects dosed in Phase 1b norovirus challenge study
norovirussource ↗
▲First Patient DosedCDI-988Trial
First subjects enrolled in Phase 1b norovirus challenge study
norovirussource ↗
▲Milestone PaymentCorporate
Received initial $225,000 of SBIR NIH grant for influenza A and B antiviral lead generation
influenza A and Bsource ↗
◆Trial InitiationCDI-988Trial
Expect to initiate CDI-988 Phase 1b norovirus challenge study
norovirussource ↗
◆Trial InitiationCDI-988Trial
Phase 1b human challenge study expected to begin before year end
norovirus infectionsource ↗
▲Trial InitiationCDI-988Trial
IRB approval from Emory University School of Medicine to initiate Phase 1b human challenge study
norovirus infectionsource ↗
●Enrollment UpdateCDI-988Trial
Initial screening of study subjects underway
norovirus infectionsource ↗
▼Equity OfferingCorporate
Private placement of 743,024 shares at $1.39 per unit for $1.03 million proceeds
▲Partnership / LicenseCorporate
Received NIH SBIR Phase I award for influenza inhibitor program
influenza A and Bsource ↗
◆Oral PresentationPresentation
Company overview presentation at Noble Capital Markets Emerging Growth Virtual Equity Conference
◆Trial InitiationCDI-988Trial
Planned initiation of Phase 1b challenge study
norovirus infectionssource ↗
▼Equity OfferingCorporate
Closing of registered direct offering raising $4.7 million upfront with potential additional $8.3 million from warrants
▲IND ClearanceCDI-988IND
FDA IND clearance for Phase 1b human challenge study
norovirus infectionsource ↗
◆Oral PresentationCDI-988Presentation
Oral presentation of Phase 1 study results for CDI-988 at 9th International Calicivirus Conference
norovirus infectionsource ↗
◆Oral PresentationPresentation
Company overview at H.C. Wainwright 27th Annual Global Investment Conference
▲IND ClearanceCDI-988IND
FDA IND clearance for Phase 1b challenge study of CDI-988
norovirus infectionssource ↗
◆Oral PresentationCDI-988Presentation
Podium presentation at 9th International Calicivirus Conference discussing CDI-988 Phase 1 data
norovirus infectionsource ↗
▼Equity OfferingCorporate
Registered direct offering and private placement of warrants in September 2025
▲FDA Feedback ReceivedCDI-988FDA Meeting
Received Study May Proceed Letter from FDA for Phase 1b challenge study
norovirussource ↗
●Oral PresentationCDI-988Presentation
Oral presentation at 9th International Calicivirus Conference
norovirussource ↗
▲Oral PresentationCDI-988Presentation
Presentation of Phase 1 results for CDI-988 at MHSRS 2025
norovirus and coronavirus infectionssource ↗
◆Oral PresentationCDI-988Presentation
Oral presentation of CDI-988 Phase 1 results at MHSRS
norovirussource ↗
▲Full ResultsCDI-988Clinical Data
Presented favorable Phase 1 safety and tolerability data at MHSRS
norovirussource ↗
Past FDA Catalysts and PDUFA Decisions
How COCP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-27 | CDI-988 (direct-acting, oral protease inhibitor) | Phase 1b data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$2M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 82%
Micro Cap(rank 540 of 658)
Percentile Rank
Cocrystal Pharma, Inc. faces pipeline headwinds (25/100), with $394M risk-adjusted pipeline value, led by CC-42344 in Influenza A (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CC-42344 Small moleculeCompletedNCT05202379 | Influenza A | Phase 2 | COMPLETED | 158 | Mar 29, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every COCP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CDI-988 Fast Track | norovirus infection | Phase 1b | 2026-05-15 | up to 40 healthy adults, aged 18 to 49, in staged cohorts; CDI‑988 is administered at 1,200 mg twice daily for five daysRead More | Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial ResultsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FROST PHILLIP MD ET ALDirector, 10% Owner | Buy | 10,000 1,993,551 held | $0.98 | 08/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in COCP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in COCP for Q2 2026. | ||||
COCP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How COCP ranks across every disease it competes in
Competitive Position is a premium feature
See how COCP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCOCP News
COCP▲ +5.1%on this news
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Cocrystal Pharma has announced the completion of dosing the last subject in its Phase 1b study for CDI-988, an oral antiviral targeting norovirus. This study aims to evaluate the drug's efficacy and safety in preventing and treating norovirus infections. Preliminary results are anticipated by late 2026 or early 2027, marking a significant step in addressing a critical public health issue.
Read more →COCPCocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
Cocrystal Pharma has appointed Dr. Carol Brosgart to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings extensive experience in antiviral therapy and has contributed to the development of FDA-approved treatments. Her expertise is expected to be crucial for advancing Cocrystal's clinical programs, particularly the CDI-988 for norovirus.
Read more →COCP▲ +14.6%on this news· ran to +26% by day 3
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
Cocrystal Pharma has secured a $5 million investment from OPKO Health, enhancing its financial position as it approaches the Phase 1b trial data for its norovirus program. The investment involves the sale of over 5.4 million shares at $0.9134 each. Cocrystal anticipates reporting topline data by the end of 2026, showcasing its commitment to developing antiviral therapeutics.
Read more →COCPCocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer
Cocrystal Pharma has appointed James Sapirstein as Chief Executive Officer, effective immediately. He replaces the previous co-CEOs and brings extensive experience in the biopharma sector. The company aims to accelerate its clinical programs for antiviral treatments using its innovative drug discovery platform. Sapirstein's leadership is expected to enhance the company's strategic direction.
Read more →COCPCocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
Cocrystal Pharma has announced the development of novel pan-viral inhibitors targeting hantavirus, bunyavirus, and influenza. These inhibitors are designed to target a conserved region of the viral replication enzyme, showing promising in vitro potency against hantavirus. The company aims to address significant unmet medical needs, particularly in light of recent outbreaks.
Read more →COCPCocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
Cocrystal Pharma has made significant strides in its antiviral pipeline, notably completing enrollment in the Phase 1b challenge study for CDI-988, which targets norovirus. The company received FDA Fast Track designation for this drug, aiming to expedite its development. Additionally, Cocrystal secured initial funding from an NIH grant to support its influenza antiviral program. However, the company reported a net loss of $2.3 million for the first quarter of 2026.
Read more →COCPCocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
Cocrystal Pharma presented its progress on CDI-988 at ICAR 2026, showcasing its mechanism of action as a treatment for norovirus infection. The drug has received FDA Fast Track designation, reflecting the urgency of addressing norovirus due to its significant health burden. Currently, CDI-988 is in a Phase 1b human challenge study, with the first cohort fully enrolled to assess infectivity. The company aims to demonstrate CDI-988's efficacy both as a preventive measure and a treatment for this prevalent infection.
Read more →COCP▲ +48%on this news
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
Cocrystal Pharma has received FDA Fast Track designation for CDI-988, an oral antiviral aimed at treating and preventing norovirus infections. This designation facilitates accelerated development and regulatory review, allowing for early communication with the FDA. A Phase 1b study is currently underway to evaluate the drug's efficacy in healthy adults. Norovirus causes significant global health and economic burdens, highlighting the need for effective treatments.
Read more →COCPCocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma has reported its 2025 financial results and provided updates on its antiviral drug development programs, particularly focusing on CDI-988, the first oral antiviral candidate for norovirus. The Phase 1b study is currently underway at Emory University, aiming to evaluate the efficacy and safety of CDI-988. Despite challenges in developing effective treatments for norovirus, the company remains optimistic about its potential as a broad-spectrum antiviral.
Read more →COCPFirst Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Cocrystal Pharma has initiated a Phase 1b study for CDI-988, an oral antiviral for norovirus. The study, conducted at Emory University, aims to evaluate CDI-988's efficacy and safety as both a treatment and preventive measure against norovirus infections. With no current approved treatments, this study addresses a significant global health challenge.
Read more →COCPCocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference
Cocrystal Pharma's CDI-988, the first oral norovirus protease inhibitor, is set to be presented at the 39th International Conference on Antiviral Research. This potentially groundbreaking antiviral drug, developed for the treatment and prevention of acute gastroenteritis caused by norovirus, will showcase Phase 1 data along with updates from its ongoing Phase 1b study. The absence of approved therapies for norovirus highlights the urgent market need this drug aims to meet, making it a significant step in antiviral research.
Read more →COCPCocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Cocrystal Pharma has received Institutional Review Board (IRB) approval from Emory University School of Medicine to initiate a Phase 1b human challenge study for its antiviral drug CDI-988, intended for the prevention and treatment of norovirus infections. Enrollment for the study is expected to begin in Q1 2026, involving healthy subjects who will be infected with norovirus to assess the drug's efficacy and safety. This represents a significant step forward in addressing a health issue with no currently approved treatments. The initiative follows prior regulatory milestones and highlights Cocrystal's innovative approach to combating norovirus outbreaks.
Read more →COCPCocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
Cocrystal Pharma will present at the 21st Emerging Growth Equity Conference hosted by Noble Capital Markets on December 3, 2025. CFO and co-CEO James Martin will discuss the company’s overview and clinical progress. The event is open to interested investors with a special registration discount. A webcast of the presentation will subsequently be available for 90 days on the company’s website, ensuring broader access to the information shared.
Read more →COCPCocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma (Nasdaq: COCP) reported its third quarter financial results for 2025 alongside key developments in its antiviral drug pipeline. The company has received FDA IND clearance to evaluate CDI-988 in a Phase 1b study aimed at both preventing and treating norovirus infections, expected to begin enrollment in Q1 2026. Furthermore, Cocrystal was awarded a NIH SBIR grant to advance its influenza replication inhibitor program. Despite these advancements, past challenges related to trial conduct and viral resistance in influenza treatments remain a concern.
Read more →COCPCocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
Cocrystal Pharma has successfully completed a private placement of units, raising $1.03 million by selling 743,024 shares at $1.39 each. The investment, primarily from company directors, reflects strong confidence in the company's future. Additionally, there is potential for $1.83 million more if warrants are fully exercised. The funds will support clinical development and general corporate purposes.
Read more →COCPCocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
Cocrystal Pharma has been awarded a $500,000 NIH SBIR Phase I grant to advance its influenza antiviral program. The funding will support the development of a novel oral antiviral candidate targeting influenza A and B. This award highlights the company's innovative drug discovery platform and opens the door for potential Phase II funding. However, there are risks related to funding delays and competition in the antiviral market.
Read more →COCPCocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Cocrystal Pharma, Inc. will present an overview at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025. CFO and co-CEO James Martin will lead the presentation, which will include a Q&A session. Investors can register for the event and schedule one-on-one meetings with Mr. Martin during the conference.
Read more →COCP▼ -7.7%on this news
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Cocrystal Pharma, Inc. has announced the successful closing of a registered direct offering, raising approximately $4.7 million upfront, with potential additional proceeds of $8.3 million from warrants. The offering was priced at $1.70 per share and aims to bolster the company's working capital. H.C. Wainwright & Co. served as the exclusive placement agent for this transaction.
Read more →COCP▼ -40.2%on this news· ran to -54% by day 3shared move
Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Cocrystal Pharma, Inc. has announced a registered direct offering of 2,764,710 shares priced at $1.70 each, aiming to raise up to $13 million. The offering includes unregistered warrants that could provide an additional $8.3 million if fully exercised. The proceeds will be used for working capital and general corporate purposes, with the closing expected around September 15, 2025.
Read more →COCP▲ +9.7%on this newsshared move
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
Cocrystal Pharma presented its lead antiviral candidate, CDI-988, at the International Calicivirus Conference. The drug, which targets norovirus, has shown promising results in Phase 1 studies, including a favorable safety profile. The company has received FDA clearance to proceed with a Phase 1b study, marking significant progress in its clinical development.
Read more →About Cocrystal Pharma, Inc.
Headquarters19805 N. CREEK PARKWAY, BOTHELL, WA, 98011
BIOPHARMAWATCH ELITE PLUS
Trade the next COCP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime